Clinical Trials /

Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy

NCT04816526

Description:

To assess Minimal Residual Disease (MRD)-negative Complete Response (sCR) rate after consolidation treatment with Descartes-08 in patients with high-risk myeloma who have residual disease following induction therapy.

Related Conditions:
  • Multiple Myeloma
Recruiting Status:

Not yet recruiting

Phase:

Phase 2

URL:

https://clinicaltrials.gov/show/NCT04816526

Trial Eligibility

Document

Title

  • Brief Title: Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
  • Official Title: Phase 2 Study of Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy

Clinical Trial IDs

  • ORG STUDY ID: DC-08-B
  • NCT ID: NCT04816526

Conditions

  • Myeloma Multiple

Interventions

DrugSynonymsArms
Descartes 08Descartes 08

Purpose

To assess Minimal Residual Disease (MRD)-negative Complete Response (sCR) rate after consolidation treatment with Descartes-08 in patients with high-risk myeloma who have residual disease following induction therapy.

Trial Arms

NameTypeDescriptionInterventions
Descartes 08Experimental
  • Descartes 08

Eligibility Criteria

        Inclusion Criteria:

          -  Patients must be 18 years of age or older at the time of enrollment

          -  High-risk multiple myeloma patients who complete pre-transplant induction treatment
             anti- myeloma drug combination (minimum 2 drugs).

        Exclusion Criteria:

          -  Patients who are pregnant or lactating.

          -  Patients who have any active and uncontrolled infection. No blood cultures are
             necessary unless clinically indicated.
Maximum Eligible Age:N/A
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Rate of stringent complete response
Time Frame:2 years
Safety Issue:
Description:

Details

Phase:Phase 2
Primary Purpose:Interventional
Overall Status:Not yet recruiting
Lead Sponsor:Cartesian Therapeutics

Last Updated

July 27, 2021